Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America The 212-patient confirmatory study...
Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration Strategic partnership spans regulatory, marketing,...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares...
U.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares...
Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030 Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing...
On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000...
50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation ...